Aftab A Malik, Iqbal Khan, Rameez Iqbal Hashmi, Mirza Tassawar Hussain, Shahid Hanef.
Effects of pamidaronate (AREDIA) on bone metastasis in patients with carcinoma of prostate.
Rawal Med J Jan ;28(1):17-21.

OBJECTIVE: am idronate, an aminobisphosphonate has been shown to lower the risk of skeletal complications associated with lytic bone lesion for up to 1 year inpatients of carcinoma with metastasis bone lesions. We have studied the efficacy and safety of 11V AREDIA 90 mg once monthly for palliation of bone pains inpatients with advanced prostate cancer. PATIENTS AND METHODS: In this study 7 patients with metastasis CA prostate and lytic bone lesion were assigned to received 90 mg IIV pamidronate monthly for 9 months for skeletal related complications which included pathologic fractures need for radiation or surgery, to treat bone complication, spinal cord compression, hypercalcemia, bone pains, analgesic were also studied. RESULTS: As the first six months of treatment, the proportion of patients with any skeletal related complications was nil for the patients with pamidronate at 12 months. The proportion of patients with any pathologic, fracture (i.e. vertebral and non vertebral fractures) need for radiation surgery to treat bone complications and hypocalcaemia were also statistically less with pamidronate. Nine months treatment did not result in any un expected adverse events. Survival has to be evaluated in follow up of patients. CONCLUSIONS: The risk of osteolytic bone lesions complication in matastasis prostate cancer was significantly decreased with monthly injection of 90 mg of pamidronate and this effect was maintained through out 9 months of treatment. Pamidronate is a useful adjuvant therapy in the pallivative treatment of metastasis prostate.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com